Valuation: CareDx, Inc.

Market Cap 3.29B 2.89B 2.73B 2.49B 4.66B 316B 4.69B 32.67B 12.65B 161B 12.37B 12.1B 518B P/E 2026 *
30.1x
P/E 2027 * 141x
Enterprise Value 3.29B 2.89B 2.73B 2.49B 4.66B 316B 4.69B 32.67B 12.65B 161B 12.37B 12.1B 518B EV / Sales 2026 *
6.65x
EV / Sales 2027 * 6.26x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day+3.76%
1 week+18.30%
Current month+27.08%
1 month+25.35%
3 months+128.65%
6 months+252.21%
Current year+238.00%
1 week 53.5
Extreme 53.5
65.19
1 month 46.69
Extreme 46.6879
65.19
Current year 15.56
Extreme 15.56
65.19
1 year 13.95
Extreme 13.95
65.19
3 years 4.8
Extreme 4.8
65.19
5 years 4.8
Extreme 4.8
75.92
10 years 0.76
Extreme 0.76
99.83
Manager TitleAgeSince
Chief Executive Officer 46 2024-04-14
Director of Finance/CFO 56 2026-02-25
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 68 2021-10-31
Chairman 59 2019-12-31
Director/Board Member 70 2014-04-07
Date Insider Type Main position Quantity % Market Cap. Importance
9/12/26 Tax

Executive/Senior Manager

-6,688 0.0129%
9/12/26 Tax

Chief Financial Officer

-8,220 0.0159%
8/5/26 Sell

General Counsel

-2,688 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
+3.76%+18.30%+328.24%+733.51% 3.29B
+1.85%+7.32%+444.55%+140.70% 4.98B
-0.47%+2.87%+124.14%+479.33% 4.7B
-6.41%+14.16%+38.42%+102.18% 3.65B
+2.50%+13.65%-9.00%-15.09% 2.58B
-4.59%-8.24%+48.11% - 1.72B
-0.65%+9.04%+182.53%-18.28% 1.13B
-0.58%+0.59%+34.12%+63.46% 1.14B
+5.08%+8.18%-25.64%+125.45% 629M
-1.62%+1.94%-30.53%-18.56% 529M
Average -0.16%+6.54%+113.50%+176.97% 2.44B
Weighted average by Cap. -0.28%+8.41%+176.25%+257.28%

Financials

2026 *2027 *
Net sales 495M 435M 410M 374M 700M 47.46B 705M 4.91B 1.9B 24.25B 1.86B 1.82B 77.92B 526M 462M 436M 398M 744M 50.45B 749M 5.22B 2.02B 25.77B 1.98B 1.93B 82.83B
Net income 116M 102M 95.99M 87.48M 164M 11.1B 165M 1.15B 445M 5.67B 435M 425M 18.23B 20.31M 17.82M 16.83M 15.34M 28.71M 1.95B 28.92M 201M 78.01M 994M 76.25M 74.6M 3.2B
Net Debt - -
Logo CareDx, Inc.
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Employees
763
Date Price Change Volume
26-09-25 US$63.68 +3.76% 2,350,726
26-09-24 US$61.37 +13.00% 2,501,407
26-09-23 US$54.31 -3.86% 1,907,390
26-09-22 US$56.49 +3.98% 1,966,547
26-09-21 US$54.33 +0.93% 766,865
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
63.68USD
Average target price
56.14USD
Spread / Average Target
-11.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CDNA Stock